Biopharma has been talking for years about the necessity for a new business model, one that reconciles the aim of expanding patient access to the latest medicine at a price point conducive to supporting future innovations. Slowly, however, complacency is giving way to experimentation. Those big pharma imperatives of size, scale and reach mean fresh opportunities for niche players willing to operate at the margin – as overall industry sales build toward the trillion-dollar mark, can there be lucre in the leftovers?
In a first for biopharma, a team of industry veterans from the virology field has seized on the precedent of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?